AVEO lands $25M milestone; MedImmune posts 184 job openings;

 @FierceBiotech: Blockbuster antibodies now face quick onslaught of biosimilars. Article | Follow @FierceBiotech

 @JohnCFierce: In a PwC survey, the FDA gets a better grade for guidance but gets an 'F' on the review process. Story | Follow @JohnCFierce

> AVEO Pharmaceuticals is in line for $25 million in milestones now that OSI has decided to exercise its option on elements of the biotech company's development platform. OSI will pay AVEO $25 million in license expansion fees; $12.5 million was paid upon delivery of the notice of option exercise and $12.5 million will be paid following the successful transfer of the applicable technology from AVEO to OSI. The transfer is expected to be completed in July 2011. Release

> MedImmune has posted 184 job openings on its web site. The biotech is filling positions in Gaithersburg and Frederick. Story

> Collegium Pharmaceutical has completed the spin-out of Onset Therapeutics, its wholly owned subsidiary focused on the dermatology market. Release

> Tolerx and the Cancer Research Institute have forged a collaboration to accelerate development of TRX518, an anti-GITR antibody for cancer. Release

> For years now biopharma companies have been developing antidepressants that can boost levels of serotonin and noradrenaline. Now a Swedish investigator at Lund University says that inflammation--which can deplete serotonin-may be a root cause of depression and a new signpost for clinicians to observe. Report

> Using magnetic resonance imaging technology, a group of researchers has identified three distinct "neural signatures"--markers that can potentially be used to identify autism at an early stage. News

> Quintiles has inked a non-exclusive deal with London Genetics Limited to offer the pharmaceutical industry pharmacogenetics solutions to advance personalized medicine. Financial terms of the deal were not disclosed. Report

> A new marker for Alzheimer's could point the way to a more effective method to treat the memory-wasting illness. Report

And Finally... UK scientists say that long index fingers are a sign of lower risk for prostate cancer. "Relative finger length could be used as a simple test for prostate cancer risk," said Ros Eeles, one of the study's lead authors. Story

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.